ReNerve gains market approval in Bahrain for NervAlign nerve cuff

• ReNerve successfully gains marketing approval in Bahrain for its nerve repair technology
• Approval follows exclusive distribution partnership for five Middle Eastern countries with Union MediScience B.S.C
• The Middle East is a key international market for ReNerve, with fewer competitors than the US

Special Report: Nerve-repair company ReNerve has secured marketing approval in Bahrain for its flagship NervAlign nerve cuff, following collaboration with regional partner Union MediScience B.S.C.

ReNerve (ASX:RNV) said the two companies would now work to commercialise NervAlign in Bahrain and use information generated from early cases to expand further regional approvals.

ReNerve said the Middle East poses strong growth potential alongside other key markets as awareness and demand for nerve repair and replacement steadily increases.

The company said market reports suggest the total Middle East and North Africa (MENA) market is worth more than US$80 million annually.

It said the MENA market is growing at more than 35%, with also fewer competitors compared to larger markets like the US.

Middle Eastern partnership in focus

Announced in December 2024, ReNerve entered an exclusive distribution partnership with the Bahrain-based Union MediScience to further accelerate its international expansion.

The partnership grants the company rights to market and sell NervAlign across five key Middle Eastern countries including Bahrain, Saudi Arabia, Kuwait, the United Arab Emirates (UAE) and Qatar.

The collaboration aims to leverage Union MediScience’s established regional network and expertise in medical products (including tissue-based products) to expedite ReNerve’s expansion.

Established in 1988, Union MediScience B.S.C is a leading medical supplier in the Middle East that represents well-known manufacturers worldwide.

ReNerve notes that Union MediScience has been a key supplier in the Bahrain market for over two decades and is well regarded for its ability to supply, install and commission products on time, tailored to customer specifications.

“The ReNerve team has done a great job on the approvals, and working with the wonderful people at Union MediScience has been excellent,” ReNerve director Dr Julian Chick said.

“We look forward to the commercialisation in Bahrain and further expanding our sales and marketing efforts in the region.”

Watch: ReNerve enters high-growth Indian market

Study finds pain relief with NervAlign

The NervAlign nerve cuff is produced using a proprietary, non-toxic process designed to protect repaired nerves and facilitate remodelling and regeneration, with absorption into surrounding tissue within six months post-repair.

The product was approved by the US Food and Drug Administration (FDA) in 2022 and is commercially available in the US.

ReNerve announced in March positive results from a nerve-repair comparative study showing patients who had peripheral nerve surgery using NervAlign had significantly lower post-surgery measures of pain to those where its nerve cuff was not used.

In April it also announced it had formed a strategic partnership with NetCentrix Ventures to enter the high-growth Indian nerve repair market, currently valued at US$115m with a compound annual growth rate of 18.5%.

This article was developed in collaboration with ReNerve, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.